Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.37 |
| ▸ | CES1 | P23141 | 5/20 | 0.36 |
| ▸ | CES2 | O00748 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28462712 | 0.97 | FAAH (0.36) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL14886372 | 0.79 | FAAH (0.32) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL28700622 | 0.76 | CES1 (0.52) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL7219721 | 0.73 | FFAR3 (0.37) | CES1CES2FFAR3TDP1ALDH1A1 | |
| SCHEMBL4643993 | 0.73 | OR51E2 (0.40) | ALDH1A1 | |
| SCHEMBL14438882 | 0.72 | FAAH (0.34) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL4999985 | 0.72 | CA2 (0.32) | FAAH | |
| SCHEMBL2392558 | 0.71 | CA4 (0.36) | — | |
| SCHEMBL7947984 | 0.71 | FFAR3 (0.35) | CES1CES2FFAR3TDP1ALDH1A1 | |
| SCHEMBL4642492 | 0.71 | TSHR (0.35) | MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8758946-B2 | Electrolyte suitable for use in a lithium ion cell or battery | GINER, INC. (US) | 2014-06-24 | — | — | US | claimed |
| US-20080193855-A1 | A lithium salt, a lithium ion solvating solvent; and fluorinated solvent; high dielectric constant, a low viscosity and a high flashpoint | GINER, INC. | 2008-08-14 | — | — | US | claimed |
| US-8835510-B2 | Methods and compositions for treating conditions mediated by oxidative stress or electrophilic environmental toxins | MONTEFIORE MEDICAL CENTER (US) | 2014-09-16 | — | — | US | disclosed |
| US-8758946-B2 | Electrolyte suitable for use in a lithium ion cell or battery | GINER, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130116337-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS MEDIATED BY OXIDATIVE STRESS OR ELECTROPHILIC ENVIRONMENTAL TOXINS | MONTEFIORE MEDICAL CENTER | 2013-05-09 | — | — | US | disclosed |
| US-20080193855-A1 | A lithium salt, a lithium ion solvating solvent; and fluorinated solvent; high dielectric constant, a low viscosity and a high flashpoint | GINER, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20070042602-A1 | Etch method using supercritical fluids | The University of Massachusetts, a Massachusetts corporations, | 2007-02-22 | — | — | US | disclosed |
| EP-1264864-B1 | Addition curable silicone composition comprising titanium chelate and a hydroxy-functional organic unsaturated compound | DOW CORNING (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20040118812-A1 | Etch method using supercritical fluids | NOVELLUS SYSTEMS, INC. | 2004-06-24 | — | — | US | disclosed |
| US-6512037-B1 | Hydrosilylation addition-curable silicone composition containing a titanium or zirconium compound having at least one aliphatic carbon-carbon multiple bond | DOW CORNING CORPORATION | 2003-01-28 | — | — | US | disclosed |
| US-20030013802-A1 | SILICONE COMPOSITION AND CURED SILICONE PRODUCT | DOW CORNING CORPORATION | 2003-01-16 | — | — | US | disclosed |
| EP-1264864-A1 | Addition curable silicone composition comprising titanium chelate and a hydroxy-functional organic unsaturated compound | Dow Corning Corporation (US) | 2002-12-11 | — | — | EP | disclosed |
| EP-1264865-A1 | Addition-curable silicone composition with improved adhesion and cured silicone product | Dow Corning Corporation (US) | 2002-12-11 | — | — | EP | disclosed |
| US-6482888-B1 | Silicone composition and cured silicone product | DOW CORNING CORPORATION | 2002-11-19 | — | — | US | disclosed |
| WO-1989004334-A1 | CURABLE COMPOSITIONS CONTAINING ETHYLENICALLY UNSATURATED MONOMERS, POLYARYLCYANATE ESTER COMPOSITIONS AND CATALYST | THE DOW CHEMICAL COMPANY (US) | 1989-05-18 | — | — | WO | disclosed |
| EP-0315089-A2 | Curable compositions containing ethylenically unsaturated monomers, polyarylcyanate ester compositions and catalyst | THE DOW CHEMICAL COMPANY (US) | 1989-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116337-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS MEDIATED BY OXIDATIVE STRESS OR ELECTROPHILIC ENVIRONMENTAL TOXINS | LPO, SOD1, SOD3 | FAAH 1498/4885CES1 484/4885CES2 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.